May 1st 2025
Aviva Capital Partners and developer Socius are investing £1 billion to develop a cancer research and treatment center in Sutton, London.
Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.
Small-Angle X-ray Scattering for Pharmaceutical Applications
October 1st 2010The author describes the development of small-angle X-ray scattering and analyzes its advantages in the characterization of drug-delivery systems and large molecules. This article is part of a special Analytical Technology issue.
How Can We Improve Dissolution Testing for Transdermals?
September 15th 2010US Pharmacopeia apparatuses for testing the dissolution of transdermal drugs produce good, reproducible results. Yet some scientists believe that further modifications could improve the instruments? suitability for this application.
Are Disposable Components Powerful Enough to Manufacture Highly Potent Drugs?
August 18th 2010Making highly potent active pharmaceutical ingredients (HPAPIs) can be costly because the process often requires equipment specialized to achieve containment and extra attention to safety concerns. Pharmaceutical professionals may wonder whether disposable components, which have reduced the cost of some operations, might be appropriate in the manufacture of HPAPIs.
Senate Introduces New Bill on Drug-Manufacturing Quality Standards
August 12th 2010Sen. Michael Bennet (D-CO) introduced a bill earlier this month, the Drug Safety and Accountability Act of 2010, which is designed to improve regulatory oversight of drug-manufacturing facilities and improve related quality standards and monitoring.
FDA Recommends Reducing Residual Drug in Transdermal Delivery Systems
August 5th 2010In a draft guidance published this week, the US Food and Drug Administration recommended that makers of transdermal and transmucosal drug-delivery systems use "an appropriate scientific approach" during product design, development, and manufacturing to minimize the amount of residual drug substance present at the end of the products' labeled use periods.